Patient reported outcomes in Triple Class Exposed, Relapsed/Refractory Multiple Myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): idecabtagene Vicleucel (ide-cel) versus standard regimens

被引：0

作者：

Einsele, H. ^{[1
]}

Delforge, M. ^{[2
]}

Patel, K. ^{[3
]}

Eliason, L. ^{[4
]}

Dhanda, D. ^{[4
]}

Shi, L. ^{[5
]}

Guo, S. ^{[5
]}

Marshall, T. ^{[4
]}

Arnulf, B. ^{[6
]}

Cavo, M. ^{[7
]}

Nooka, A. ^{[8
]}

Manier, S. ^{[9
]}

Callander, N. ^{[10
]}

Giralt, S. ^{[11
]}

Ailawadhi, S. ^{[12
]}

McKiver, Popa M. ^{[4
]}

Cook, M. ^{[13
]}

Rodriguez Otero, P. ^{[14
]}

机构：

[1] Uniklinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Univ Hosp Leuven, Leuven, Belgium

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Bristol Myers Squibb, Princeton, NJ USA

[5] Evidera, Bethesda, MD USA

[6] Hop St Louis, Paris, France

[7] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[8] Emory Univ, Winship Canc Inst, Atlanda, GA USA

[9] Ctr Hosp Univ Lille, Lille, France

[10] Univ Wisconsin Hlth, Madison, WI USA

[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[12] Mayo Clin, Jacksonville, FL 32224 USA

[13] Celgene Int Sarl, Boudry, Switzerland

[14] Clin Univ Navarra, Pamplona, Spain

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V545

引用

页码：83 / 83

页数：1

共 50 条

[31] KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma
Delforge, Michel
Baz, Rachid C.
Cavo, Michele
Callander, Natalie S.
Ghobadi, Armin
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Massaro, Monica
Ding, Li
Patel, Payal
Pittari, Gianfranco
Novick, Steven
Giralt, Sergio A.
Berdeja, Jesus G.
BLOOD, 2020, 136
[32] Patient (pt) Experiences of Receiving Idecabtagene Vicleucel (Ide-Cel, bb2121) Versus Standard (Std) Regimens for the Treatment (Tx) of Relapsed/Refractory Multiple Myeloma (RRMM) in the Randomized, Controlled KarMMa-3 Clinical Trial: Analysis of Longitudinal Qualitative Interviews
Rodriguez Otero, Paula
Patel, Krina K.
Raje, Noopur S.
Moshkovich, Olga
Gerould, Heather
Devlen, Jennifer
Dhanda, Devender
Eliason, Laurie
Cook, Mark
Popa-McKiver, Mihaela
Manier, Salomon
BLOOD, 2023, 142
[33] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
Berdeja, Jesus G.
Raje, Noopur S.
Siegel, David S.
Lin, Yi
Anderson, Larry D., Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Einsele, Hermann
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy B.
Jagannath, Sundar
BLOOD, 2020, 136
[34] Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma
Kansagra, Ankit
Lin, Yi
Berdeja, Jesus G.
Shah, Nina
Oriol, Albert
Yakoub-Agha, Ibrahim
Einsele, Hermann
Rambaldi, Alessandro
Truppel-Hartmann, Anna
Rowe, Everton
Wang, Julie
Agarwal, Amit
Campbell, Timothy B.
Lonial, Sagar
BLOOD, 2020, 136
[35] KarMMa study: Characterization of Cytokine Release Syndrome (CRS) in patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with Idecabtagene Vicleucel (ide-cel, bb2121)
Einsele, H.
Kansagra, A.
Lin, Y.
Berdeja, J.
Shah, N.
Oriol, A.
Yakoub-Agha, I
Rambaldi, A.
Truppel-Hartmann, A.
Rowe, E.
Wang, J.
Agarwal, A.
Campbell, T. B.
Lonial, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 208 - 209
[36] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma in the pivotal phase 2 KarMMa study
Weisel, K.
Manier, S.
Kansagra, A.
Anderson, Jr L. D.
Berdeja, J.
Jagannath, S.
Lin, Y.
Lonial, S.
Shah, N.
Raje, N.
Siegel, D.
Oriol, A.
Truppel-Hartmann, A.
Rowe, E.
Patel, P.
Agarwal, A.
Campbell, T. B.
Rodriguez-Otero, P.
Munshi, N.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 179 - 180
[37] ESTIMATION OF POST-INFUSION COSTS OF CARE FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVED IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN THE KARMMA CLINICAL TRIAL
Hari, P.
Nguyen, A.
Pelletier, C.
Hege, K.
McGarvey, N.
Gitlin, M.
Parikh, K.
VALUE IN HEALTH, 2021, 24 : S29 - S30
[38] Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial
Ayers, Dieter
Cope, Shannon
Dhanda, Devender S.
Towle, Kevin
Mojebi, Ali
Delforge, Michel
Rodriguez-Otero, Paula
Trudel, Suzanne
Weisel, Katja
Zamagni, Elena
Hari, Parameswaran
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S139 - S140
[39] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS
Cavo, M.
Oriol, A.
San-Miguel, J.
Kansagra, A.
Madduri, D.
Shah, N.
Moreau, P.
Yakoub-Agha, I.
Delforge, M.
Einsele, H.
Goldschmidt, H.
Weisel, K.
Rambaldi, A.
Reece, D.
Rodriguez-Otero, P.
Petrocca, F.
Connarn, J.
Patel, P.
Huang, L.
Campbell, T.
Hege, K.
Munshi, N.
HAEMATOLOGICA, 2021, 106 (10) : 5 - 5
[40] The B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell Therapy Idecabtagene Vicleucel (Ide-Cel; Bb2121) in Relapsed and Refractory Multiple Myeloma (Rrmm): Outcomes from a Phase 1 Study Support the Phase 3 Karmma-3 Study Design to Compare IDE-Cel Versus Standard Triplet Regimens
Einsele, Hermann
Raab, Marc
Kroeger, Nicolaus
Fenk, Roland
Scheid, Christoph
Munshi, Nikhil
Petrocca, Fabio
Hege, Kristen
Novick, Steven
Raje, Noopur
Kochenderfer, James
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 213 - 213

← 1 2 3 4 5 →